McKenna Mark C. has filed 15 insider transactions across 4 companies since August 2023.
Most recent transaction: a grant/award of 3400 shares of NewAmsterdam Pharma Co N.V. ($NAMS) on January 07, 2026.
Activity breakdown: 2 open-market purchases and 0 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 7, 2026 | NewAmsterdam Pharma Co N.V. | $NAMS | McKenna Mark C. | Not found | A | Ordinary Shares | 3400 | $0.00 | 10,360.0000 | 119,000,266 | 48.85% | 0.00% |
| Jan. 7, 2026 | NewAmsterdam Pharma Co N.V. | $NAMS | McKenna Mark C. | Not found | A | Option (right to buy) | 15300 | $0.00 | 15,300.0000 | 119,000,266 | 9999.99% | 0.01% |
| Aug. 11, 2025 | BridgeBio Oncology Therapeutics, Inc. | $BBOT | McKenna Mark C. | Other | M | Class B ordinary shares | 30000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Aug. 11, 2025 | BridgeBio Oncology Therapeutics, Inc. | $BBOT | McKenna Mark C. | Other | M | Common Stock | 30000 | $0.00 | 30,000.0000 | 0 | 9999.99% | 0.00% |
| June 17, 2025 | Apogee Therapeutics, Inc. | $APGE | McKenna Mark C. | Director | A | Stock Option (Right to Buy) | 14461 | $0.00 | 14,461.0000 | 46,016,542 | 9999.99% | 0.03% |
| May 29, 2025 | Spyre Therapeutics, Inc. | $SYRE | McKenna Mark C. | Director | A | Stock Option (Right to Buy) | 25000 | $0.00 | 25,000.0000 | 60,275,561 | 9999.99% | 0.04% |
| Jan. 7, 2025 | NewAmsterdam Pharma Co N.V. | $NAMS | McKenna Mark C. | Not found | A | Ordinary Shares | 6960 | $0.00 | 6,960.0000 | 94,358,067 | 9999.99% | 0.01% |
| Jan. 6, 2025 | NewAmsterdam Pharma Co N.V. | $NAMS | McKenna Mark C. | Not found | A | Option (right to buy) | 32500 | $0.00 | 32,500.0000 | 94,358,067 | 9999.99% | 0.03% |
| Dec. 12, 2024 | Apogee Therapeutics, Inc. | $APGE | McKenna Mark C. | Director | P | Common Stock | 7500 | $49.02 | 7,500.0000 | 0 | 9999.99% | 0.00% |
| Dec. 12, 2024 | Apogee Therapeutics, Inc. | $APGE | McKenna Mark C. | Director | P | Common Stock | 12500 | $49.85 | 20,000.0000 | 0 | 166.67% | 0.00% |
| July 17, 2024 | NewAmsterdam Pharma Co N.V. | $NAMS | McKenna Mark C. | Not found | A | Option (right to buy) | 72500 | $0.00 | 72,500.0000 | 82,161,956 | 9999.99% | 0.09% |
| June 5, 2024 | Apogee Therapeutics, Inc. | $APGE | McKenna Mark C. | Director | A | Stock Option (Right to Buy) | 10370 | $0.00 | 10,370.0000 | 0 | 9999.99% | 0.00% |
| Feb. 1, 2024 | Spyre Therapeutics, Inc. | $SYRE | McKenna Mark C. | Not found | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 0 | 9999.99% | 0.00% |
| Aug. 17, 2023 | Apogee Therapeutics, Inc. | $APGE | McKenna Mark C. | Director | A | Stock Option (Right to Buy) | 50000 | $0.00 | 50,000.0000 | 0 | 9999.99% | 0.00% |
| Aug. 17, 2023 | Apogee Therapeutics, Inc. | $APGE | McKenna Mark C. | Director | A | Stock Option (Right to Buy) | 100000 | $0.00 | 150,000.0000 | 0 | 200.00% | 0.00% |